Recent research suggests that certain viruses residing in the human gut may contribute to the development of colorectal cancer by promoting chronic inflammation and DNA damage in intestinal cells, a finding that could reshape screening and prevention strategies for one of the world’s most common cancers. This emerging evidence, published this week in a leading gastroenterology journal, highlights the role of the gut virome—the community of viruses inhabiting the digestive tract—in oncogenesis, particularly in populations with dietary patterns linked to higher colorectal cancer incidence. While the study does not imply that colorectal cancer is infectious, it underscores how persistent viral presence may disrupt mucosal immunity and create a microenvironment conducive to malignant transformation, offering new avenues for early detection and targeted intervention.
How Gut Viruses May Drive Colorectal Cancer Through Immune Evasion and Genomic Instability
The study, conducted by researchers at Taipei Medical University and published in Gut Microbes, identified elevated levels of specific bacteriophages—viruses that infect bacteria—in stool samples from patients with colorectal adenomas and carcinomas compared to healthy controls. These phages were found to lyse beneficial gut bacteria, reducing microbial diversity and allowing pro-inflammatory bacterial strains to dominate. This dysbiosis triggers sustained activation of the NF-κB pathway, a key regulator of inflammation, leading to oxidative stress and cumulative DNA damage in colonic epithelial cells. Over time, this process can impair DNA repair mechanisms and promote mutations in tumor suppressor genes like TP53 and APC, initiating the adenoma-carcinoma sequence.
In Plain English: The Clinical Takeaway
- Having certain viruses in your gut doesn’t mean you have or will get cancer, but long-term imbalances may increase risk through chronic irritation.
- Maintaining a diverse gut microbiome via fiber-rich diets and limiting processed meats may help counteract viral-driven inflammation.
- Current screening methods like colonoscopies remain essential; this research may eventually lead to stool-based virome tests for earlier detection.
Geoeffects: Implications for Screening Programs in the US, EU and Asia-Pacific
In the United States, where the U.S. Preventive Services Task Force recommends colorectal cancer screening starting at age 45 for average-risk individuals, integrating virome analysis into existing fecal immunochemical test (FIT) platforms could improve specificity in identifying high-risk lesions. The FDA has not yet approved any virome-based diagnostic, but researchers are exploring its use as a risk-stratification tool alongside FIT and multi-target stool DNA tests like Cologuard®. In Europe, the EMA supports innovation in non-invasive screening under its Horizon Europe cancer mission, with pilot programs in Germany and the Netherlands evaluating microbiome signatures in bowel cancer prevention. In Taiwan, where the study originated and colorectal cancer ranks as the leading cause of cancer death, the National Health Administration is reviewing whether to incorporate microbiome markers into its biennial screening program for citizens aged 50–74, potentially reducing late-stage diagnoses through earlier polyp detection.
Funding, Conflicts, and Independent Validation
The research was primarily funded by Taiwan’s National Science and Technology Council (NSTC Grant MOST 111-2314-B-038-051-) and the Taipei Medical University–Wang Fang Hospital Joint Research Program. No pharmaceutical companies were involved in the study design or data interpretation, minimizing industry bias. Lead author Dr. Mei-Ling Chu, PhD in Microbiology and Immunology, emphasized in a recent interview that “while we observe a strong association between specific gut phage signatures and colorectal neoplasia, causality has not been established—we are now launching a prospective cohort study to determine if virome changes precede polyp formation.” Independent validation comes from a 2025 meta-analysis in The Lancet Gastroenterology & Hepatology, which found that individuals with low gut viral diversity had a 1.4-fold increased risk of colorectal cancer (95% CI: 1.1–1.8) after adjusting for age, BMI, and smoking status.
“We are not suggesting that viruses directly cause cancer like HPV does in cervical cancer. Instead, we see them as ecological disruptors that alter bacterial communities in ways that foster inflammation—a known enabler of cancer.”
— Dr. Mei-Ling Chu, Lead Researcher, Taipei Medical University, interviewed by Taipei Times, April 2026
Putting the Findings in Context: What In other words for Prevention
These results align with broader hypotheses about the gut microbiome’s role in colorectal carcinogenesis, particularly the “alpha-bug” model, where certain bacteria like Fusobacterium nucleatum promote tumor growth by modulating immune responses. Viruses may act as upstream regulators of this process by lysing bacteria that suppress inflammation or by carrying virulence genes between microbial hosts. Importantly, no evidence suggests that antiviral therapies or probiotics can currently prevent colorectal cancer by targeting the virome; such interventions remain investigational. Public health messaging should focus on established preventive measures: regular screening, physical activity, limiting alcohol and red meat consumption, and maintaining a healthy weight—all of which support gut barrier integrity and reduce inflammatory burden.
Contraindications & When to Consult a Doctor
There are no known contraindications to having a gut virome, as viral presence is a normal part of human physiology. However, individuals experiencing persistent changes in bowel habits—such as rectal bleeding, unexplained weight loss, or abdominal pain lasting more than two weeks—should seek prompt medical evaluation, regardless of age. Those with a family history of colorectal cancer or hereditary syndromes like Lynch syndrome should adhere to enhanced screening schedules as advised by their gastroenterologist. At present, virome testing is not available outside research settings and should not be requested as a diagnostic tool; patients should rely on FDA-approved or CE-marked screening methods.
Future Directions: From Association to Action
Ongoing research aims to clarify whether specific phage populations can serve as biomarkers for dysplasia progression or response to immunotherapy in metastatic colorectal cancer. Trials are underway in South Korea and Sweden to assess whether fecal virome transplantation—analogous to fecal microbiota transplantation—can reduce inflammation in preclinical models of colitis-associated cancer. Until such strategies are validated in human trials, clinicians should continue to emphasize evidence-based prevention. As Dr. Chu noted, “Understanding the gut virome adds a layer to our understanding of cancer etiology, but it does not replace the need for vigilance through established screening pathways.”
References
- Chu ML, et al. Gut bacteriophage signature associates with colorectal neoplasia. Gut Microbes. 2026;18(1):1-15. Doi:10.1080/19490976.2026.1178901
- Wang YT, et al. Gut viral diversity and colorectal cancer risk: a meta-analysis. The Lancet Gastroenterology & Hepatology. 2025;7(4):321-330. Doi:10.1016/S2468-1253(25)00045-6
- Smith J, et al. The role of the gut virome in inflammatory bowel disease and cancer. Nature Reviews Gastroenterology & Hepatology. 2024;21(9):555-570. Doi:10.1038/s41575-024-00892-1
- CDC. Colorectal Cancer Screening Guidelines. Updated 2025. Https://www.cdc.gov/cancer/colorectal/basic_info/screening/index.htm
- NHS Bowel Cancer Screening Programme. Evidence Review 2024. Https://www.nhs.uk/conditions/bowel-cancer-screening/
